MERCK KGAA
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1668-01-01
- Employees
- 62.9K
- Market Cap
- $84.2B
- Website
- http://www.merckgroup.com/de
A Prospective, Multi-centric Observational Study to Determine the Mono-bifollicular Development in Infertile Women Subjected to Ovulation Induction With Follitropin α
Completed
- Conditions
- Ovulation Induction
- First Posted Date
- 2010-04-27
- Last Posted Date
- 2014-07-16
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 410
- Registration Number
- NCT01111084
- Locations
- 🇪🇸
Hospital Ntra. Sra. De Valme, Sevilla, Spain
An Observational Study to Evaluate Quality of Life (QoL) and Influence of Cognitive Status on QoL in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS) During 2 Years Treatment With Rebif New Formulation (RNF)
Completed
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- First Posted Date
- 2010-04-27
- Last Posted Date
- 2014-02-03
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 65
- Registration Number
- NCT01110993
- Locations
- 🇵🇱
Medical University, Department of Neurology, Lublin, Poland
A Randomised, Phase II, Comparative Study With a Parallel Control for Evaluating the Efficacy and Safety of Combined Treatment of Lutropin Alpha and Recombinant Human Luteinizing Hormone in the Middle of the Controlled Ovarian Stimulation Follicular Phase in Women With Reduced Ovarian Reserve
Phase 2
Completed
- Conditions
- Ovulation InductionInfertility
- Interventions
- Drug: Recombinant human luteinizing hormone (r-hLH)Drug: Recombinant human follicle stimulating hormone (r-hFSH)
- First Posted Date
- 2010-04-27
- Last Posted Date
- 2018-03-27
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 131
- Registration Number
- NCT01110707
- Locations
- 🇪🇸
Hospital de Cruces, Plaza de Cruces, 12, 48903, Vizcaya, Spain
Efficacy and Safety Evaluation of Recombinant Human Growth Hormone (r-hGH), Saizen®, on a Population of Children With Hypochondroplasia, Treated at Least 3 Years or Until Near Final Height, When Applicable, in Comparison With a Historic Cohort of Non-treated Children
Phase 2
Completed
- Conditions
- Hypochondroplasia
- Interventions
- Drug: Recombinant human growth hormone (r-hGH)
- First Posted Date
- 2010-04-27
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 19
- Registration Number
- NCT01111019
- Locations
- 🇫🇷
Endocrinologie Pédiatrique - centre des maladies rares de la croissance -Hôpital Necker Enfants Malades, Paris, France
An Observational Study of Cetrotide® Gonadotropin-releasing Hormone Antagonist (GnRH Antagonist) With GONAL-f® in Assisted Reproductive Technologies (ART)
Completed
- Conditions
- Infertility
- First Posted Date
- 2010-04-23
- Last Posted Date
- 2014-07-16
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 2175
- Registration Number
- NCT01109654
- Locations
- 🇸🇬
Singapore General Hospital Pte Ltd, Outram Road, Singapore, Singapore
Bisoprolol in Hypertension: Effect on Concomitant Elevated Heart Rate
Completed
- Conditions
- Hypertension
- First Posted Date
- 2010-04-22
- Last Posted Date
- 2014-07-31
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 351
- Registration Number
- NCT01109043
- Locations
- 🇦🇹
Merck Serono Research Site, Vienna, Austria
An Observational Study for the Assessment of Adherence, Effectiveness and Convenience of Rebif® Treatment in Relapsing Multiple Sclerosis Patients Using RebiSmart™.
Completed
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- First Posted Date
- 2010-04-22
- Last Posted Date
- 2013-09-17
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 912
- Registration Number
- NCT01108887
- Locations
- 🇳🇱
Merck Serono Observational Site, Breda, Netherlands
Association Between Genetic Polymorphism of Beta-adrenergic Receptor and Effects of Bisoprolol in Korean Heart Failure Patients.
Phase 4
Completed
- Conditions
- Chronic Heart Failure
- First Posted Date
- 2010-04-15
- Last Posted Date
- 2014-02-13
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 100
- Registration Number
- NCT01104558
- Locations
- 🇰🇷
The Catholic University of Korea Seoul St. Mary's Hospital, 505, Banpodong, SeoChoGu, Seoul, Korea, Republic of
Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting.
Completed
- Conditions
- Multiple Sclerosis
- First Posted Date
- 2010-04-12
- Last Posted Date
- 2014-08-13
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 49
- Registration Number
- NCT01101776
- Locations
- 🇦🇺
Merck Serono Research Site, Perth, Western Australia, Australia
GONAL-f CONSORT (Consistency in r-hFSH Starting Doses for Individualised Treatment)
Completed
- Conditions
- Infertility
- First Posted Date
- 2010-04-08
- Last Posted Date
- 2014-07-31
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 2552
- Registration Number
- NCT01100333
- Locations
- 🇩🇪
Universitätsmedizin Charitè Berlin, Schumann Straße 20/21, Berlin, Germany
© Copyright 2025. All Rights Reserved by MedPath